Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Cancer Conference Journal
Published in: International Cancer Conference Journal 2/2018

01-04-2018 | Case report

Progression to bone-marrow carcinomatosis and extraosseous legion during treatment with radium-223 for multiple bone metastases

Authors: Takahiko Hajime, Masaki Shiota, Tatsuro Abe, Ario Takeuchi, Shingo Baba, Junichi Inokuchi, Katsunori Tatsugami, Yoshinao Oda, Hiroshi Honda, Masatoshi Eto

Published in: International Cancer Conference Journal | Issue 2/2018

Login to get access

Abstract

A 67-year-old man with metastatic prostate cancer presented with progression to castration-resistant prostate cancer. After sequential therapies with flutamide, estramustine phosphate, docetaxel, enzalutamide, and cabazitaxel for castration-resistant prostate cancer, radium-223 was initiated and continued up to 4 cycles. However, concurrently with radiological and clinical progressions, pancytopenia was observed due to bone-marrow carcinomatosis by prostatic adenocarcinoma. This case suggested that radium-223 should be employed at appropriated timing before appearances of extraosseous and bone-marrow lesions in addition to visceral metastasis.
Literature
1.
Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223CrossRefPubMed
2.
Bruland ØS, Nilsson S, Fisher DR et al (2006) High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 12:6250s–6257sCrossRefPubMed
3.
McKay RR, Jacobus S, Fiorillo M et al (2017) Radium-223 use in clinical practice and variables associated with completion of therapy. Clin Genitourin Cancer 15:e289–e298CrossRefPubMed
4.
Lassmann M, Nosske D (2013) Dosimetry of 223Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging 40:207–212CrossRefPubMed
5.
Esposito G, Antonelli F, Belli M et al (2009) An alpha-particle irradiator for radiobiological research and its implementation for bystander effect studies. Radiat Res 172:632–642CrossRefPubMed
6.
7.
Casimiro S, Ferreira AR, Mansinho A et al (2016) Molecular mechanisms of bone metastasis: which targets came from the bench to the bedside? Int J Mol Sci 17:E1415CrossRefPubMed
8.
Kratochwil C, Afshar-Oromieh A, Kopka K et al (2016) Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer. Semin Nucl Med 46:405–418CrossRefPubMed
Metadata
Title
Progression to bone-marrow carcinomatosis and extraosseous legion during treatment with radium-223 for multiple bone metastases
Authors
Takahiko Hajime
Masaki Shiota
Tatsuro Abe
Ario Takeuchi
Shingo Baba
Junichi Inokuchi
Katsunori Tatsugami
Yoshinao Oda
Hiroshi Honda
Masatoshi Eto
Publication date
01-04-2018
Publisher
Springer Japan
Published in
International Cancer Conference Journal / Issue 2/2018
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-017-0316-8

Other articles of this Issue 2/2018

International Cancer Conference Journal 2/2018 Go to the issue

Case report

Para-sacral approach for large gastrointestinal stromal tumor of the lower rectum

Case report

Successful radiotherapy for endometrial serous carcinoma with local repeated recurrence

Case Report

Malignant triton tumor of the duodenum: report of a case

Case report

A case of the cirrhotic patient performed living donor liver transplantation after carbon-ion radiotherapy for hepatocellular carcinoma

Video Article

Laparoscopic transhiatal lymphadenectomy in the lower mediastinum for adenocarcinoma of the esophagogastric junction

Case report

A case of mature cystic teratoma with intestinal structures harboring intestinal-type low-grade mucinous neoplasm
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits